Comparison of Filgrastim and Its Biosimilars in Cancer Chemotherapy

Ruoyu Ning

doi:10.54097/j3wa5w62

Authors

Ruoyu Ning

DOI:

https://doi.org/10.54097/j3wa5w62

Keywords:

Filgrastim, biosimilar, cancer chemotherapy, chemotherapy-induced neutropenia.

Abstract

Chemotherapy-induced neutropenia (CIN) is a common and serious complication in cancer patients, potentially leading to febrile neutropenia (FN), increased risk of infection, and delayed chemotherapy, severely impacting treatment efficacy and patient prognosis. Filgrastim (FIL), a granulocyte colony-stimulating factor (G-CSF) drug, significantly reduces the incidence of FN by stimulating neutrophil proliferation and differentiation. This article systematically reviews the molecular structure, mechanism of action, pharmacokinetic characteristics, and efficacy of FIL in cancer chemotherapy. This article also provides an in-depth comparative analysis of the structural consistency and clinical efficacy of various FIL biosimilars. Numerous clinical studies and data demonstrate that these biosimilars are equivalent to the original drug, Neupogen®, in terms of efficacy and safety, while significantly reducing treatment costs and improving patient accessibility and compliance. Although additional follow-up data are needed for some biosimilars regarding immunogenicity and long-term interchangeability, current evidence suggests their potential for broad clinical application. Future efforts should strengthen monitoring of the long-term effects of biosimilars and optimize their structural properties to further enhance their quality consistency and global accessibility.

Downloads

Download data is not yet available.

References

[1] Blackwell, K., Donskih, R., Jones, C. M., ... & Harbeck, N. (2016). A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: Pegfilgrastim randomized oncology (supportive care) trial to evaluate comparative treatment (PROTECT-2), a phase III, randomized, double-blind trial. The Oncologist, 21(7), 789–794.

[2] Crawford, J., Ozer, H., Stoller, R., ... & Glaspy, J. (1994). Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. Clinical Infectious Diseases, 18(Supplement_2), S189–S196.

[3] Dimitrijevic, J., & Stojanović, M. (2022). Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors. Medicinski Podmladak, 73(2), 1–5.

[4] El-Shakankery, S., Gabriel, S., & Groves, E. (2019). Prophylactic use of filgrastim on days 7, 11 and 14 in patients receiving R-CHOP for non-Hodgkin's lymphoma. Blood, 134, 5887.

[5] Filho, A. M., Laversanne, M., Ferlay, J., ... & Bray, F. (2025). The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. International Journal of Cancer, 156(7), 1336–1346.

[6] Gascon, P., Jankowsky, R., & Roth, K. (2017). Perspectives on the future of pegfilgrastim biosimilars. Generics and Biosimilars Initiative Journal, 6(4), 185–187.

[7] Harris, C. T., & Cohen, S. (2024). Reducing immunogenicity by design: Approaches to minimize immunogenicity of monoclonal antibodies. BioDrugs, 38(2), 205–226.

[8] Mantovani, M., Caruso, C. S., et al. (2016). Physicochemical and biological comparison of the first Brazilian biosimilar filgrastim with its reference product. Biosimilars, 45–60.

[9] Marjoncu, D. (2023). A review of clinical data among biosimilars: Just how similar are they? Journal of Hematology Oncology Pharmacy, 13(4).

[10] Rastogi, S., Kalaiselvan, V., Ali, S., et al. (2021). Efficacy and safety of filgrastim and its biosimilars to prevent febrile neutropenia in cancer patients: A prospective study and meta-analysis. Biology, 10(10), 1069.

[11] Zhao, Q., Zhang, H. J., Han, M. M., ... & Jia, Y. L. (2025). Advances in cell cycle regulation to enhance recombinant protein production in CHO cells. Biochimie.